Journal
NATURE REVIEWS NEPHROLOGY
Volume 13, Issue 12, Pages 728-729Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrneph.2017.140
Keywords
-
Categories
Funding
- Boehringer Ingelheim
Ask authors/readers for more resources
New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
